Differences in Alzheimer's disease blood biomarker stability: Implications for the use of tau/amyloid ratios DOI Creative Commons
Daniel Figdore,

Bethany J. Schuder,

Susan Ashrafzadeh‐Kian

et al.

Alzheimer s & Dementia, Journal Year: 2025, Volume and Issue: 21(4)

Published: April 1, 2025

We compare the stability of phosphorylated tau (p-tau)217, amyloid beta (Aβ)42, Aβ40, Aβ42/40, and p-tau217/Aβ42 at different storage temperatures. Ten ethylenediaminetetraacetic acid-plasma sample aliquots stored frozen, refrigerated, ambient temperatures were tested various timepoints up to 30 days. The mean percent change from baseline was calculated. Aβ42 Aβ40 concentrations decreased by >15% after 6 hours temperature 24 while p-tau217 remained stable over 72 with < 10% deviation either temperature. Aβ42/40 ratio relatively constant as each analyte concentration concurrently, deviated time. All biomarkers days frozen. Differences in may lead altered results if samples are not handled properly during pre-analytical testing phase. Ideally, should be frozen promptly sent laboratory Plasma assessed. P-tau217 stable, but started decreasing differences led falsely increased ratios. Increases > 15% seen or 4°C.

Language: Английский

Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use DOI Creative Commons
Michael Schöll, Agathe Vrillon, Takeshi Ikeuchi

et al.

The Journal of Prevention of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown, P. 100056 - 100056

Published: Jan. 1, 2025

As novel, anti-amyloid therapies have become more widely available, access to timely and accurate diagnosis has integral ensuring optimal treatment of patients with early-stage Alzheimer's disease (AD). Plasma biomarkers are a promising tool for identifying AD pathology; however, several technical clinical factors need be considered prior their implementation in routine use. Given the rapid pace advancements field wide array available tests, this review aims summarize these considerations, evaluate platforms, discuss steps needed bring plasma biomarker testing clinic. We focus on phosphorylated(p)-tau, specifically p-tau217, as robust candidate across both primary secondary care settings. Despite high performance robustness demonstrated research, like all biomarkers, can affected by analytical pre-analytical variability well patient comorbidities, sex, ethnicity, race. This also discusses advantages two-point cut-off approach mitigating factors, challenges raised resulting intermediate range measurements, where guidance is still unclear. Further validation p-tau217 heterogeneous, real-world cohorts will help increase confidence support establishing standardized approach. poised affordable less invasive alternative PET CSF testing. However, understanding that impact measurement interpretation critical

Language: Английский

Citations

3
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease DOI Creative Commons
Michael Schöll, Inge M.W. Verberk, Marta del Campo

et al.

The Lancet Healthy Longevity, Journal Year: 2024, Volume and Issue: 5(10), P. 100630 - 100630

Published: Oct. 1, 2024

Language: Английский

Citations

15
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform DOI Creative Commons
Francisco Martínez‐Dubarbie, Armando Ruiz, Sara López‐García

et al.

The Journal of Prevention of Alzheimer s Disease, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

Citations

4
Core blood biomarkers of Alzheimer's disease: A single-center real-world performance study DOI Creative Commons
Federico Emanuele Pozzi,

Elisa Conti,

Giulia Remoli

et al.

The Journal of Prevention of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: 12(2), P. 100027 - 100027

Published: Jan. 23, 2025

Language: Английский

Citations

0
The impact of pre-analytical factors on plasma biomarkers for Alzheimer's disease: The ASPREE Healthy Ageing Biobank DOI Creative Commons
Zimu Wu, Michelle M. Mielke, Anne M. Murray

et al.

The Journal of Prevention of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown, P. 100058 - 100058

Published: Feb. 1, 2025

The conditions under which samples were collected, processed, and stored in biobanks may influence Alzheimer's disease (AD) biomarker levels. This study aims to investigate whether a range of pre-analytical factors plasma levels AD biomarkers. Data obtained from the ASPREE Healthy Ageing Biobank, cohort healthy community-dwelling older individuals aged 70+ years Australia. Five biomarkers measured using 11,868 individuals: phosphorylated-tau181 (p-tau181), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), amyloid-beta 42 40 (Aβ42/Aβ40). Linear regression examined association between Participants 70-96 years, 54 % female. mean storage time for was 10.6 (range: 7.7-13.5). Some significant associations identified biomarkers, particular p-tau181, but effect sizes small. Weak negative found p-tau181 venepuncture laboratory (transport) (β: -0.82, p = 0.03), processing frozen (β:-1.56, < 0.001), total -0.45, 0.007), while positive with intermediate at -20 °C/-30 °C compared -80 2.24, 0.004). Longer fasting associated higher both NfL 0.15, 0.001) GFAP 1.75, 0.001). Following standard operating procedures, can be up 13 minimal impact long-term or other factors.

Language: Английский

Citations

0
Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis DOI Creative Commons
Annibale Antonioni,

Emanuela Maria Raho,

Francesco Di Lorenzo

et al.

Journal of Neurology, Journal Year: 2025, Volume and Issue: 272(3)

Published: March 1, 2025

Alzheimer's disease (AD) is the leading cause of dementia worldwide, and cost-effective tools to detect amyloid pathology are urgently needed. Blood-based Tau phosphorylated at threonine 217 (pTau217) seems promising, but its reliability as a proxy for cerebrospinal fluid (CSF) status ability identify patients within AD spectrum remain unclear. We performed systematic review meta-analysis on potential blood pTau217 differentiate amyloid-positive (A+) amyloid-negative (A-) subjects. included original studies reporting quantitative data concentrations in both CSF continuum. The single-group computed pooled levels CSF, separately A+ A- groups, while head-to-head compared mean versus subjects, stratifying by assessment method cases. Ten (819 A+; 1055 A-) were included. resulted higher than and, crucially, individuals ones, regardless laboratory employed. Most importantly, all techniques reliably distinguished from whether applied or samples. These results confirm that blood-based reliable marker with significant implications clinical practice Indeed, might be non-invasive, scalable biomarker early detection, reducing reliance more invasive, expansive, less accessible methods. Prospero CRD42024565187.

Language: Английский

Citations

0
Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform DOI Creative Commons
Francisco Martínez‐Dubarbie, Armando Ruiz, Sara López‐García

et al.

Alzheimer s Research & Therapy, Journal Year: 2025, Volume and Issue: 17(1)

Published: March 27, 2025

Plasma biomarkers for Alzheimer's disease (AD) are a promising tool accessible and accurate biological diagnostics. However, data in clinical practice needed to better understand their diagnostic prognostic ability memory unit patients. We analyzed plasma phosphorylated tau at threonine 217 (p-tau217) neuroflament light chain (NfL) levels AD cerebrospinal fluid (CSF) group of 493 subjects using the Lumipulse G600II platform. The sample includes 340 patients from our (142 dementia, 186 mild cognitive impairment, 12 with subjective complaints) 153 cognitively unimpaired volunteers. have correlated CSF biomarkers; we biomarker as function diagnosis, status amyloid status. also studied p-tau217 discriminate between amyloid-positive -negative according receiver operating characteristic curves. significantly Aβ42/Aβ40 (Rho = -0.75; p-value < 0.001), p-tau181 (r 0.66; t-tau 0.59; 0.001). NfL 0.48; By showed be higher than healthy controls (difference 0.63 pg/ml; FTD 0.60 nondegenerative dementias 0.61 an area under curve 0.95 A + A- (95%CI 0.93–0.97). shows excellent results detecting pathology brain level setting AUC 0.95. It is highly specific marker increases progressively along continuum. Using initial cut-offs sensitivities specificities 95 or 97.5% could save 57.4–84.8% LP/PETs accuracies 95–97%. different stages.

Language: Английский

Citations

0
Differences in Alzheimer's disease blood biomarker stability: Implications for the use of tau/amyloid ratios DOI Creative Commons
Daniel Figdore,

Bethany J. Schuder,

Susan Ashrafzadeh‐Kian

et al.

Alzheimer s & Dementia, Journal Year: 2025, Volume and Issue: 21(4)

Published: April 1, 2025

We compare the stability of phosphorylated tau (p-tau)217, amyloid beta (Aβ)42, Aβ40, Aβ42/40, and p-tau217/Aβ42 at different storage temperatures. Ten ethylenediaminetetraacetic acid-plasma sample aliquots stored frozen, refrigerated, ambient temperatures were tested various timepoints up to 30 days. The mean percent change from baseline was calculated. Aβ42 Aβ40 concentrations decreased by >15% after 6 hours temperature 24 while p-tau217 remained stable over 72 with < 10% deviation either temperature. Aβ42/40 ratio relatively constant as each analyte concentration concurrently, deviated time. All biomarkers days frozen. Differences in may lead altered results if samples are not handled properly during pre-analytical testing phase. Ideally, should be frozen promptly sent laboratory Plasma assessed. P-tau217 stable, but started decreasing differences led falsely increased ratios. Increases > 15% seen or 4°C.

Language: Английский

Citations

0